We are live on ! Find out more
SCPH

scPharmaceuticals

Delisted

SCPH was delisted on the 6th of October, 2025.

38 hedge funds and large institutions have $75.9M invested in scPharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 3738 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.69% less ownership

Funds ownership: 58.03%57.34% (-0.69%)

16% less capital invested

Capital invested by funds: $90.1M → $75.9M (-$14.2M)

Holders
38
Holders Change
+1
Holders Change %
+2.7%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
16
Reduced
10
Closed
3
Calls
Puts
Net Calls
Net Calls Change

SCPH Hedge Fund Activity: Q2 2022 in Review

38 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2022, worth a combined $75.9M — down 16% from $90.1M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SCPH positions and 3 closed out — a net gain of 1 holder — while 16 added to existing stakes and 10 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $13.4M. The largest seller was RA Capital Management, exiting entirely with an estimated $15.1M sold.

  • 38 institutional investors held scPharmaceuticals (SCPH) as of Q2 2022, up from 37 in Q1 2022.
  • Funds reported $75.9M of scPharmaceuticals stock for Q2 2022, down 16% quarter-over-quarter.
  • 4 funds opened new scPharmaceuticals positions in Q2 2022 and 3 closed out, a net change of +1 holder.
  • The largest scPharmaceuticals buyer in Q2 2022 was Armistice Capital, an estimated $13.4M added.
  • The largest scPharmaceuticals seller in Q2 2022 was RA Capital Management, an estimated $15.1M sold.

Based on aggregated 13F filings for Q2 2022.